Johnson & Johnson (JNJ) — closed signal from January 3, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 3, 2026.
Predicted vs. what happened
What happened
Reached its target in 25 days.
The thesis — published January 3, 2026
JNJ looks like a defensive stock that recently fell more than usual, and analysts expect a temporary rebound. The company announced its dividend payable March 10, which makes it appealing to investors seeking steady income. Because the overall trend is still weak, any recovery could be gradual and should be confirmed before committing more money.
Primary drivers
- Dividend news strengthens its role as a stable income stock
- Recent heavy selling increases chance of a short-term rebound
- Healthcare businesses tend to hold up better in turbulent markets
- Defined entry range lets you place a tight risk limit
How it played out
JNJ: target reached in 25 days
Lyra published JNJ at $207.35 on 2026-01-03 with a short-term thesis for 9% growth. The thesis pointed to dividend news, recent heavy selling, the defensive profile of healthcare businesses, and a defined $203 to $208 entry range. It expected a rebound, but also said the broader trend was still weak and any recovery could be gradual.
Inside the window, JNJ reached a peak of $251.71 on 2026-03-02. That was a 21.4% gain, and the $226.01 target was reached in 25 days. The stock ended the window at $243.04 on 2026-04-03. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.